Eikon Therapeutics, Inc. (NasdaqGS: EIKN)
Health Care · Biotechnology · US
$7.26
-2.81% today · -51.6% 1Y
Eikon Therapeutics, Inc. (NasdaqGS: EIKN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $393.24M and employs 384 people.
Over the last twelve months the share price has lost 51.6%, trading between 7.02 and 17.40.
Tweenvest scores Eikon Therapeutics, Inc. across four factors: quality 43/100, value 66/100. Its strongest factor is value.
EIKN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $393.24M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -13.72
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $17.40
- 52-week low
- $7.02
- Avg volume (3M)
- —
- Shares outstanding
- 54.17M
- Employees
- 384
- Next earnings
- —
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
- ISIN
- US2825641036
- Founded
- 2019
- Listed since
- Feb 5, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AP Biosciences, Inc.TPEX: 6945 | $405.68M | NT$133.00 | -2.21% |
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $400.65M | $3.74 | -3.86% |
| Laekna, Inc.SEHK: 2105 | $400.21M | HK$7.37 | -15.77% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $397.35M | $3.87 | -1.78% |
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $390.53M | $12.61 | -8.22% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $387.40M | $30.46 | -2.31% |
| Opus Genetics, Inc.NasdaqCM: IRD | $386.03M | $4.64 | -0.22% |
| Formycon AGXTRA: FYB | $384.18M | €19.46 | +2.10% |
Figures last refreshed Oct 11, 2026.